ReviewLeukemia2003
Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate.
Review in Leukemia, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00408278 (Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia), which is not on this map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005): Remission Induction With ATRA + Idarubicin. Risk-adapted Consolidation With ATRA and Anthracycline-based Chemotherapy (Idarubicin/Mitoxantrone) With Addition of Ara-C for High-risk Patients. Maintenance Therapy With ATRA + Low Dose Chemotherapy (Methotrexate + Mercaptopurine).
Who cites it
45 citing papers in PubMed.
- Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.Leukemia · 2006Trial
- Arsenome, Arsenobolome, and Arsenobiolome.International journal of molecular sciences · 2025Review
- Aleukemic Acute Promyelocytic Leukemia: How Concomitant HIV, Hepatitis C, and Chronic Alcohol Use Disorder May Have Hidden an Underlying Malignancy.The American journal of case reports · 2023Article
- ZNF117 regulates glioblastoma stem cell differentiation towards oligodendroglial lineage.Nature communications · 2022Article
- Regulation of N6-Methyladenosine in the Differentiation of Cancer Stem Cells and Their Fate.Frontiers in cell and developmental biology · 2020Review
- Identification and characterization of a phenyl-thiazolyl-benzoic acid derivative as a novel RAR/RXR agonist.Heliyon · 2019Article
- Therapeutic targeting of gastrointestinal cancer stem cells.Regenerative medicine · 2019Review
- Meta-Analysis of Gene Expression Profiles in Acute Promyelocytic Leukemia Reveals Involved Pathways.International journal of hematology-oncology and stem cell research · 2017Article
- Refractory acute promyelocytic leukemia successfully treated with combination therapy of arsenic trioxide and tamibarotene: A case report.Leukemia research reports · 2016Article
- Acute promyelocytic leukemia harbouring rareOncology letters · 2015Article
- [Involvement of oxidative stress in embelin-induced cell death in leukemia HL-60 cells].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2015Article
- Extramedullary relapse in lumbar spine of patient with acute promyelocytic leukemia after remission for 16 years: a case report and literature review.International journal of clinical and experimental medicine · 2015Article
- De-differentiation confers multidrug resistance via noncanonical PERK-Nrf2 signaling.PLoS biology · 2014Article
- CPEB1 modulates differentiation of glioma stem cells via downregulation of HES1 and SIRT1 expression.Oncotarget · 2014Article
- Hepatocellular Carcinoma: Basic and Transitional Research.Gastrointestinal tumors · 2014Review
- How I treat children and adolescents with acute promyelocytic leukaemia.British journal of haematology · 2014Review
- Gastric cancer stem cells: therapeutic targets.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2014Review
- Lung cancer-initiating cells: a novel target for cancer therapy.Targeted oncology · 2013Review
- Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.International journal of hematology · 2013Review
- Update on optimal management of acute myeloid leukemia.Clinical Medicine Insights. Oncology · 2013Article
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute promyelocytic leukemia (APL) has become a curable disease by all-trans retinoic acid (ATRA)-based induction therapy followed by two or three courses of consolidation chemotherapy. Currently around 90% of newly diagnosed patients with APL achieve complete remission (CR) and over 70% of patients are curable. To further increase the CR and cure rates, detection and diagnosis of this disease at its early stage is very important, hopefully before the appearance of APL-associated coagulopathy. In induction therapy, concomitant chemotherapy is indispensable, except for patients with low initial leukocyte counts. Prophylactic use of intrathecal methotrexate and cytarabine should be done, particularly for patients with hyperleukocytosis. If patients relapse hematologically or even molecularly, arsenic trioxide will be the treatment of choice under careful electrocardiogram monitoring. Am80, liposomal ATRA, gemtuzumab ozogamicin or ATRA in combination with cytotoxic drugs may be used at this stage or later. Allogeneic SCT will be the treatment of choice after patients of age <50 years have relapsed, provided that they have HLA-identical family donors or DNA-identical unrelated donors.
Indexed as
Identifiers
12886231What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.